Lentiviral vector (LVV) production for CAR-T cell therapy requires sophisticated process control and optimization strategies. Our experience scaling LVV production to clinical-grade specifications demonstrates the importance of parameter optimization, process control, and quality assurance.

Key process parameters include multiplicity of infection (MOI), cell density at transfection, culture duration, and downstream processing conditions. Each parameter directly impacts final titer and vector quality attributes.

Scaling from lab-scale (1L) to manufacturing (2-cell stack, 500L+) requires careful validation of critical process parameters. We have consistently achieved titers of 10⁹-10¹⁰ TU/ml meeting clinical-grade specifications.

Quality attributes monitored include vector titer, transduction efficiency, endotoxin levels, sterility, and potency. Integration of real-time process monitoring enables rapid identification and correction of process deviations.

Regulatory compliance throughout the manufacturing process ensures rapid approval pathways and market readiness for CAR-T therapy products.